Antag Therapeutics has initiated a first-in-human, double-blind Phase Ia trial of the glucose-dependent insulinotropic ...

GLP-1 receptor agonists were associated with improved survival and reduced graft loss among kidney transplant recipients with type 2 diabetes.

Spending on glucagon-like peptide-1 receptor agonists (GLP-1 RAs) increased from 2018 to 2023, with the largest growth rates from 2022 to 2023. Although spending for certain GLP-1 RAs increased ...

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

Manufactured by Novo Nordisk, semaglutide is the newest in a family of glucagon-like peptide-1 receptor agonists used most commonly to treat type II diabetes. To date, the results of semaglutide for ...

The drug is a first-of-its-kind treatment for obesity as well as type 2 diabetes as it activates both GIP (glucose-dependent polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors.

New Delhi [India], March 20 (ANI): Global pharmaceutical company Eli Lilly and Company (India) has introduced Mounjaro (tirzepatide) in India, a breakthrough drug for the treatment of Type 2 ...

It is a first-of-its-kind treatment for obesity, overweight, and type 2 diabetes that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone ...

(RTTNews) - OPKO Health (OPK) and Entera Bio have entered a collaboration and license agreement to develop the first oral dual agonist GLP-1/glucagon peptide for obesity, metabolic, and fibrotic ...